NDC 55135-132

TRODELVY

Sacituzumab Govitecan

TRODELVY is a Intravenous Powder, For Solution in the Human Prescription Drug category. It is labeled and distributed by Immunomedics, Inc.. The primary component is Sacituzumab Govitecan.

• Product ID: 55135-132_03cd6297-513e-469a-a1d1-da5400fb5099
• NDC: 55135-132
• Product Type: Human Prescription Drug
• Proprietary Name: TRODELVY
• Generic Name: Sacituzumab Govitecan
• Dosage Form: Powder, For Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2020-04-22
• Marketing Category: BLA / BLA
• Application Number: BLA761115
• Labeler Name: Immunomedics, Inc.
• Substance Name: SACITUZUMAB GOVITECAN
• Active Ingredient Strength: 180 mg/1
• NDC Exclude Flag: N
• Listing Certified Through: 2022-12-31

Packaging

NDC 55135-132-01

1 VIAL in 1 BOX (55135-132-01) > 1 POWDER, FOR SOLUTION in 1 VIAL

• Marketing Start Date: 2020-04-23
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 55135-132-01 [55135013201]

TRODELVY POWDER, FOR SOLUTION

• Marketing Category: BLA
• Application Number: BLA761115
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: EA
• Marketing Start Date: 2020-04-23

Drug Details

Active Ingredients

Ingredient	Strength
SACITUZUMAB GOVITECAN	180 mg/1

OpenFDA Data

• SPL SET ID: 57a597d2-03f0-472e-b148-016d7169169d
• Manufacturer:
  • Immunomedics, Inc.
• UNII:
  • M9BYU8XDQ6
• RxNorm Concept Unique ID - RxCUI:
  • 2360539
  • 2360534
• UPC Code:
  • 0355135132011